文献速递炎症性肠病

乌帕替尼治疗在诱导治疗第1天即可减轻溃疡性结肠炎症状

Upadacitinib Therapy Reduces Ulcerative Colitis Symptoms as Early as Day 1 of Induction Treatment.
PubMed 文献 · Clin Gastroenterol Hepatol · 2022-12-01

该研究基于两项3期多中心诱导试验(U-ACHIEVE和U-ACCOMPLISH)的汇总数据,纳入988例溃疡性结肠炎患者(安慰剂328例,乌帕替尼45 mg每日一次660例),分析用药后14天内的症状日记。结果显示乌帕替尼组在第1至3天即出现所有溃疡性结肠炎症状的显著改善并维持至第14天,第2周临床缓解/应答率显著高于安慰剂,且早期症状改善与第8周临床缓解/应答显著相关。

要点

  • 乌帕替尼45 mg每日一次从第1天起即显著改善溃疡性结肠炎症状,并维持至第14天。
  • 第2周时乌帕替尼组部分Mayo评分临床缓解/应答率分别为26.9%/59.4%,显著高于安慰剂组的4.3%/22.3%(P < .001)。
  • 第3天排便频率和便急迫的早期改善及第2周hs-CRP和FCP的下降与第8周临床缓解/应答显著相关。

核心结论

  • 乌帕替尼45 mg每日一次可从第1天起快速缓解溃疡性结肠炎症状。

研究设计与样本

  • 对两项重复的3期多中心诱导试验U-ACHIEVE Induction和U-ACCOMPLISH的汇总数据进行事后分析。
  • 共分析988例患者,其中安慰剂组328例,乌帕替尼45 mg每日一次组660例。
  • 分析从首次给药至第14天的日记卡数据,评估溃疡性结肠炎症状(排便频率、直肠出血、腹痛和便急迫)的每日改善。
  • 在第2周评估炎症标志物高敏C反应蛋白(hs-CRP)和粪便钙卫蛋白(FCP)的变化,在第2周和第8周评估生活质量。
  • 采用回归分析确定溃疡性结肠炎症状变化与第8周达到Adapted Mayo评分临床缓解/应答可能性之间的关联。

主要发现

  • 乌帕替尼组在第1天至第3天之间所有溃疡性结肠炎症状较安慰剂组出现显著改善,并维持至第14天。
  • 分别有75.7%和48.2%的患者达到hs-CRP和FCP水平较基线下降>50%(与安慰剂相比P < .001)。
  • 从第2周起,乌帕替尼45 mg每日一次组部分Mayo评分临床缓解/应答率分别为26.9%/59.4%,安慰剂组分别为4.3%/22.3%(P < .001)。
  • 第2周和第8周观察到生活质量的显著改善。
  • 第3天排便频率和便急迫的早期改善以及第2周hs-CRP和FCP的下降与第8周临床缓解/应答显著相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: We evaluated the efficacy of once-daily (QD) upadacitinib 45 mg, an oral, reversible Janus kinase inhibitor, on early symptomatic improvement for ulcerative colitis (UC). Post hoc analyses were performed on pooled data from 2 replicate, phase 3, multicenter induction trials, U-ACHIEVE Induction and U-ACCOMPLISH, to determine the earliest time point of efficacy onset. METHODS: Diary entry data through 14 days from the first dose of placebo or upadacitinib 45 mg QD were analyzed for daily improvement in UC symptoms (stool frequency, rectal bleeding, abdominal pain, and bowel urgency). Changes in inflammatory markers, high-sensitivity C-reactive protein (hs-CRP), and fecal calprotectin (FCP) were assessed at week 2 and quality of life (QoL) at weeks 2 and 8. Regression analysis determined the association between changes in UC symptoms and the likelihood of achieving clinical remission/response per Adapted Mayo score at week 8. RESULTS: Overall, 988 patients (n = 328 placebo, n = 660 upadacitinib) were analyzed. Patients treated with upadacitinib demonstrated significant improvements vs placebo in all UC symptoms between days 1 and 3 and maintained through day 14. A >50% reduction from baseline in hs-CRP and FCP levels was achieved by 75.7% and 48.2% of patients, respectively (P < .001 vs placebo). Increased rates of clinical remission/response per Partial Mayo score from week 2 (26.9%/59.4% upadacitinib 45 mg QD vs 4.3%/22.3% placebo, P < .001) and significant improvements in QoL at weeks 2 and 8 were observed. Early improvement in stool frequency and bowel urgency by day 3 and reductions in hs-CRP and FCP by week 2 were significantly associated with clinical remission/response at week 8. CONCLUSIONS: Upadacitinib 45 mg QD provided rapid relief of UC symptoms from day 1. CLINICALTRIALS: gov: U-ACHIEVE Induction (NCT02819635) and U-ACCOMPLISH (NCT03653026).

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Loftus EV, Colombel JF, Takeuchi K, et al. Upadacitinib Therapy Reduces Ulcerative Colitis Symptoms as Early as Day 1 of Induction Treatment. Clin Gastroenterol Hepatol. 2022. PMID: 36464141. doi:10.1016/j.cgh.2022.11.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。